Pink SheetThe Biden Administration’s policies on price inflation rebates in Medicare and Medicaid unintentionally provided President Trump a tool to amplify the threat tariffs would pose to pharma. But Trump’s
ScripExelixis may have a steady source of revenue after cabozantinib – approved as Cabometyx and Cometriq – loses market exclusivity, after zanzalintinib delivered positive pivotal Phase III results in col
ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
ScripWelsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in